Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE-BDLL: BDLLfxC Regimen for Rifampin-Resistant TB
NCT06649721Phase 3Active, not recruiting
- Sponsor
- Huashan Hospital
- Start
- Nov 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bedaquiline, delamanid, linezolid, levofloxacin and clofazimine in pulmonary tuberculosis (TB), sponsored by Huashan Hospital. Primary endpoint: Proportion of participants with favorable outcomes in both treatment and follow-up period at 72 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
bedaquilinedelamanidlinezolidlevofloxacinclofazimine
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06649721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649721.